ASB Consultores LLC Sells 64 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ASB Consultores LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 512 shares of the biopharmaceutical company’s stock after selling 64 shares during the quarter. ASB Consultores LLC’s holdings in Regeneron Pharmaceuticals were worth $538,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in REGN. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth $28,000. Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $33,000. Finally, Family Firm Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of REGN opened at $828.84 on Tuesday. The firm has a market cap of $91.37 billion, a P/E ratio of 20.51, a P/E/G ratio of 2.90 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1 year low of $783.57 and a 1 year high of $1,211.20. The stock has a 50 day simple moving average of $1,051.02 and a two-hundred day simple moving average of $1,040.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on REGN shares. Evercore ISI lowered their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Leerink Partners reissued a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,097.25.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.